144 related articles for article (PubMed ID: 34605771)
1. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Bunderen CC; van Varsseveld NC; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Eur J Endocrinol; 2014 Dec; 171(6):717-26. PubMed ID: 25227133
[TBL] [Abstract][Full Text] [Related]
3. Analysis of short- and long-term metabolic effects of growth hormone replacement therapy in adult patients with craniopharyngioma and non-functioning pituitary adenoma.
Profka E; Giavoli C; Bergamaschi S; Ferrante E; Malchiodi E; Sala E; Verrua E; Rodari G; Filopanti M; Beck-Peccoz P; Spada A
J Endocrinol Invest; 2015 Apr; 38(4):413-20. PubMed ID: 25330765
[TBL] [Abstract][Full Text] [Related]
4. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
[TBL] [Abstract][Full Text] [Related]
6. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.
Ragnarsson O; Höybye C; Jönsson PJ; Feldt-Rasmussen U; Johannsson G; Biller BM; Koltowska-Häggström M
Eur J Endocrinol; 2012 Apr; 166(4):593-600. PubMed ID: 22258111
[TBL] [Abstract][Full Text] [Related]
7. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
[TBL] [Abstract][Full Text] [Related]
8. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
[TBL] [Abstract][Full Text] [Related]
9. Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone Replacement.
Yuen KCJ; Mattsson AF; Burman P; Erfurth EM; Camacho-Hubner C; Fox JL; Verhelst J; Geffner ME; Abs R
J Clin Endocrinol Metab; 2018 Feb; 103(2):768-777. PubMed ID: 29029108
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Cardiovascular Risk With Arterial Stiffness in Patients with Nonfunctioning Pituitary Adenoma.
Çağır Y; Altay M; Çağır BB; Çakal E; Akkan T; Yıldız C; Ünsal Y; Dağdeviren M; Beyan E
Endocr Pract; 2018 Sep; 24(9):815-822. PubMed ID: 29975581
[TBL] [Abstract][Full Text] [Related]
11. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study.
Smith TR; Cote DJ; Jane JA; Laws ER
J Neurosurg Pediatr; 2016 Oct; 18(4):408-412. PubMed ID: 27286443
[TBL] [Abstract][Full Text] [Related]
12. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.
Maiter D; Abs R; Johannsson G; Scanlon M; Jönsson PJ; Wilton P; Koltowska-Häggström M
Eur J Endocrinol; 2006 Aug; 155(2):253-60. PubMed ID: 16868138
[TBL] [Abstract][Full Text] [Related]
13. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
[TBL] [Abstract][Full Text] [Related]
14. New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.
Krzyzanowska-Mittermayer K; Mattsson AF; Maiter D; Feldt-Rasmussen U; Camacho-Hübner C; Luger A; Abs R
J Clin Endocrinol Metab; 2018 Feb; 103(2):523-531. PubMed ID: 29228199
[TBL] [Abstract][Full Text] [Related]
15. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy.
Holmer H; Ekman B; Björk J; Nordstöm CH; Popovic V; Siversson A; Erfurth EM
Eur J Endocrinol; 2009 Nov; 161(5):671-9. PubMed ID: 19667040
[TBL] [Abstract][Full Text] [Related]
16. Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Ubachs DH; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
J Clin Endocrinol Metab; 2015 Mar; 100(3):1104-12. PubMed ID: 25574793
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.
Höybye C; Ragnarsson O; Jönsson PJ; Koltowska-Häggström M; Trainer P; Feldt-Rasmussen U; Biller BM
Eur J Endocrinol; 2010 Apr; 162(4):677-84. PubMed ID: 20089548
[TBL] [Abstract][Full Text] [Related]
18. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database.
Gardner CJ; Mattsson AF; Daousi C; Korbonits M; Koltowska-Haggstrom M; Cuthbertson DJ
Eur J Endocrinol; 2015 Apr; 172(4):371-81. PubMed ID: 25583905
[TBL] [Abstract][Full Text] [Related]
19. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
[TBL] [Abstract][Full Text] [Related]
20. Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.
Oh JS; Kim HJ; Hann HJ; Kang TU; Kim DS; Kang MJ; Lee JY; Shim JJ; Lee MR; Ahn HS
Pituitary; 2021 Feb; 24(1):38-47. PubMed ID: 32949324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
